Pulmonology

As recently as 2010, anywhere from 18% to 36% of pediatric asthma cases were driven by traffic-related air pollution.

Results suggest doctors may be able to delay onset of lung disease in children born with CF.

The LAMA/LABA combination therapy was shown to reduce one-year exacerbation rates while not increasing patient risk of cardiovascular events.

Investigators found in animal models that pulmonary endothelial function was influenced by caloric intake rates.

The study will focus on a dozen-plus children with severe asthma over a period of 4 weeks.

The oral tablet generics approvals also come with 2 approved shared system REMS programs for ambrisentan.

New research shows the public increasingly sees e-cigarettes as equally unhealthy compared to cigarettes—but that’s not the whole picture.

Higher exposure to air pollutants, especially NO2 and NOx, was found to be associated with greater odds of psychotic experiences in adolescents.

The investigational anti-fibrotic immunomodulator is being investigated for respiratory, oncology, hepatology, and nephrology indications.

The dual-acting dopamine and norepinephrine reuptake inhibitor is the first approved to treat excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.

Until recently, there's been little providers or parents could do, beyond offering supportive care, to improve outcomes for children with SMA. But there is new hope.

Largest birth cohort study to date strengthens link between infant bronchiolitis and later respiratory disease.

Little is known on the underlying pulmonary arterial lesions in patients with this phenotype of COPD.

Observed data from a 96,000-plus participant survey found the popularized cigarette alternative is also associated with a greater risk of depression.

Eosinophilic asthma is characterized by elevated levels of eosinophils, which are a direct cause of chronic inflammation in severe asthma.

A new study reports an independent association between air pollution and arterial inflammation—and that the former could serve as a predictor to events like stroke and myocardial infarction.

Studies show that more than 90% of EoE patients improve symptoms with food elimination therapy. Should more patients be in touch with allergists?

This is the third indication for the biologic therapy, following its approvals for adult AD and moderate to severe asthma maintenance care.

The biologic has been previously approved for adult atopic dermatitis and uncontrolled asthma, and is being assesed for another half-dozen allergic/immunologic indications.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

According to investigators, recent trial results indicate no other biologic treatment has shown as rapid onset than benralizumab for patients with eosinophilic asthma.

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

In this phase 3 study, dupilumab improved outcomes for patients with recurring severe chronic rhinosinusitis with nasal polyps.